Gül Dölen

And then it closes. So we think that after they've, you know, done as much as they can during that two months, three months after the stroke with the physical therapy, but they haven't recovered full motion yet, we can give them psychedelics and keep it open a little bit longer. Keep the PT going. Keep it going.

And then it closes. So we think that after they've, you know, done as much as they can during that two months, three months after the stroke with the physical therapy, but they haven't recovered full motion yet, we can give them psychedelics and keep it open a little bit longer. Keep the PT going. Keep it going.

And then it closes. So we think that after they've, you know, done as much as they can during that two months, three months after the stroke with the physical therapy, but they haven't recovered full motion yet, we can give them psychedelics and keep it open a little bit longer. Keep the PT going. Keep it going.

Actually, though, in the first version of this trial, what we're going to do is we're going to take people who had a stroke over a year ago. So their critical period is closed down. Hard and fast shut. Hard closed. And then we're going to try and reopen in those people and see what happens to their ability to pair that psychedelic with physical therapy this time instead of psychotherapy.

Actually, though, in the first version of this trial, what we're going to do is we're going to take people who had a stroke over a year ago. So their critical period is closed down. Hard and fast shut. Hard closed. And then we're going to try and reopen in those people and see what happens to their ability to pair that psychedelic with physical therapy this time instead of psychotherapy.

Actually, though, in the first version of this trial, what we're going to do is we're going to take people who had a stroke over a year ago. So their critical period is closed down. Hard and fast shut. Hard closed. And then we're going to try and reopen in those people and see what happens to their ability to pair that psychedelic with physical therapy this time instead of psychotherapy.

There is evidence that there is only so many times that you can take these psychedelics before they stop working in this way. There's evidence, you know, anecdotally from... recreational users who estimate that you've got about 20 or 30 really big MDMA trips and then you're done and it loses its magic after that.

There is evidence that there is only so many times that you can take these psychedelics before they stop working in this way. There's evidence, you know, anecdotally from... recreational users who estimate that you've got about 20 or 30 really big MDMA trips and then you're done and it loses its magic after that.

There is evidence that there is only so many times that you can take these psychedelics before they stop working in this way. There's evidence, you know, anecdotally from... recreational users who estimate that you've got about 20 or 30 really big MDMA trips and then you're done and it loses its magic after that.

Right, right. Yeah, I agree. I'm hopeful. I mean, we don't know. This is really, I'm speculating now. But if this is the case, maybe you use up all of your MDMA slots, but you've never done Ibogaine. And so you can still have an Ibogaine in reserve that you could tap into to reopen. But, you know, this remains to be seen. Hmm.

Right, right. Yeah, I agree. I'm hopeful. I mean, we don't know. This is really, I'm speculating now. But if this is the case, maybe you use up all of your MDMA slots, but you've never done Ibogaine. And so you can still have an Ibogaine in reserve that you could tap into to reopen. But, you know, this remains to be seen. Hmm.

Right, right. Yeah, I agree. I'm hopeful. I mean, we don't know. This is really, I'm speculating now. But if this is the case, maybe you use up all of your MDMA slots, but you've never done Ibogaine. And so you can still have an Ibogaine in reserve that you could tap into to reopen. But, you know, this remains to be seen. Hmm.

Totally.

Totally.

Totally.

For me personally, the thing that I'm most excited about is, you know, if we're right about this master key business, then what it means is, is that there's a lot of other diseases that psychedelics are not being explored for that really we should be thinking about. Right.

For me personally, the thing that I'm most excited about is, you know, if we're right about this master key business, then what it means is, is that there's a lot of other diseases that psychedelics are not being explored for that really we should be thinking about. Right.

For me personally, the thing that I'm most excited about is, you know, if we're right about this master key business, then what it means is, is that there's a lot of other diseases that psychedelics are not being explored for that really we should be thinking about. Right.

that will have implications for people with cochlear implants, people with traumatic brain injury, all kinds of other diseases that really right now we just don't have any therapy for.

that will have implications for people with cochlear implants, people with traumatic brain injury, all kinds of other diseases that really right now we just don't have any therapy for.